RecruitingNot Applicable

Metabolomics Study on Postoperative Intensive Care Acquired Muscle Weakness

Austria, Germany20 participantsStarted 2022-09-02

Plain-language summary

In this mono-center pilot trial, surgical patients who are at high risk to be admitted to intensive care will be screened and asked for participation. We are going to take blood and muscle samples at respecified time points to do metabolic, histological and molecular testing. Aim of the study is to investigate (1) changes of the blood metabolome in patients with ICUAW (intensive care unit acquired weakness) and (2) identify metabolic components who are responsible for ICUAW or can be used as marker for ICUAW.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * invasive mechanically ventilated critically ill patient with expected intensive care unit stay \> 3 days * postoperative patient * ≥ 18 years old * American Society of Anesthesiology (ASA) classification ≥ III Exclusion Criteria: * moribund patient * non-curative care (comfort care)

What they're measuring

Metabolomics

Timeframe: a median of 14 days

Trial details

NCT IDNCT03810768

SponsorTechnical University of Munich

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-11-01

Contact for this trial

Stefan J Schaller, MD

+4314040041020 stefan.schaller@meduniwien.ac.at

View on ClinicalTrials.gov More Metabolomics trials